{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:33Z","timestamp":1740106953957,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T00:00:00Z","timestamp":1544832000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\/TRR79, subproject B10"],"award-info":[{"award-number":["SFB\/TRR79, subproject B10"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00210-018-01602-1","type":"journal-article","created":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T14:22:12Z","timestamp":1544883732000},"page":"461-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro"],"prefix":"10.1007","volume":"392","author":[{"given":"Julia","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4720-9242","authenticated-orcid":false,"given":"Dirk","family":"Theile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,15]]},"reference":[{"key":"1602_CR1","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1345\/aph.1E620","volume":"39","author":"P Andr\u00e9","year":"2005","unstructured":"Andr\u00e9 P, Cisternino S, Chiadmi F, Toledano A, Schlatter J, Fain O, Fontan JE (2005) Stability of bortezomib 1-mg\/mL solution in plastic syringe and glass vial. Ann Pharmacother 39:1462\u20131466","journal-title":"Ann Pharmacother"},{"key":"1602_CR2","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","volume":"124","author":"B Barlogie","year":"2014","unstructured":"Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J (2014) Curing myeloma at last: defining criteria and providing the evidence. Blood 124:3043\u20133051","journal-title":"Blood"},{"key":"1602_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ejps.2010.07.015","volume":"41","author":"DR Barpe","year":"2010","unstructured":"Barpe DR, Rosa DD, Froehlich PE (2010) Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci 41:458\u2013463","journal-title":"Eur J Pharm Sci"},{"key":"1602_CR4","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","volume":"113","author":"G Bianchi","year":"2009","unstructured":"Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, Palladini G, Giuliani N, Anderson KC, Sitia R, Cenci S (2009) The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113:3040\u20133049","journal-title":"Blood"},{"key":"1602_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.chroma.2014.04.024","volume":"1345","author":"J Clemens","year":"2014","unstructured":"Clemens J, Longo M, Seckinger A, Hose D, Haefeli WE, Weiss J, Burhenne J (2014) Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr A 1345:128\u2013138","journal-title":"J Chromatogr A"},{"key":"1602_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00280-014-2643-1","volume":"75","author":"J Clemens","year":"2015","unstructured":"Clemens J, Seckinger A, Hose D, Theile D, Longo M, Haefeli WE, Burhenne J, Weiss J (2015) Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. Cancer Chemother Pharmacol 75:281\u2013291","journal-title":"Cancer Chemother Pharmacol"},{"key":"1602_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","volume":"169","author":"GA Collins","year":"2017","unstructured":"Collins GA, Goldberg AL (2017) The logic of the 26S proteasome. Cell 169:792\u2013806","journal-title":"Cell"},{"key":"1602_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","volume":"44","author":"D Czock","year":"2005","unstructured":"Czock D, Keller F, Rasche FM, H\u00e4ussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61\u201398","journal-title":"Clin Pharmacokinet"},{"key":"1602_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00210-016-1276-9","volume":"389","author":"S Dettmer","year":"2016","unstructured":"Dettmer S, Theile D, Sch\u00e4fer J, Seckinger A, Burhenne J, Weiss J (2016) Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines. Naunyn Schmiedeberg\u2019s Arch Pharmacol 389:1091\u20131101","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"1602_CR10","unstructured":"Ema.europa.eu [Internet]. London (UK): assesment report Neofordex [cited: 2018 May 18th]. Available from: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Application_withdrawal_assessment_report\/human\/002418\/WC500177562.pdf"},{"key":"1602_CR11","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P (2017) Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia 31:1915\u20131921","journal-title":"Leukemia"},{"key":"1602_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/01.cco.0000142072.22226.09","volume":"16","author":"O Frankfurt","year":"2004","unstructured":"Frankfurt O, Rosen ST (2004) Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol 16:553\u2013563","journal-title":"Curr Opin Oncol"},{"key":"1602_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG (2017) The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev 36:561\u2013584","journal-title":"Cancer Metastasis Rev"},{"key":"1602_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10495-006-0624-5","volume":"12","author":"I Herr","year":"2007","unstructured":"Herr I, Gassler N, Friess H, B\u00fcchler MW (2007) Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids. Apoptosis 12:271\u2013291","journal-title":"Apoptosis"},{"key":"1602_CR15","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/leu.2015.80","volume":"29","author":"EK Mai","year":"2015","unstructured":"Mai EK, Bertsch U, D\u00fcrig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H (2015) Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 29:1721\u20131729","journal-title":"Leukemia"},{"key":"1602_CR16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Oriol A, Mart\u00ednez-L\u00f3pez J, Guti\u00e9rrez N, Teruel AI, de Paz R, Garc\u00eda-Lara\u00f1a J, Bengoechea E, Mart\u00edn A, Mediavilla JD, Palomera L, de Arriba F, Gonz\u00e1lez Y, Hern\u00e1ndez JM, Sureda A, Bello JL, Bargay J, Pe\u00f1alver FJ, Ribera JM, Mart\u00edn-Mateos ML, Garc\u00eda-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalb\u00e1n MA, Lahuerta JJ, Blad\u00e9 J, Miguel JF (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11:934\u2013941","journal-title":"Lancet Oncol"},{"key":"1602_CR17","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s00277-016-2835-3","volume":"95","author":"MV Mateos","year":"2016","unstructured":"Mateos MV, Oriol A, Mart\u00ednez-L\u00f3pez J, Teruel AI, Bengoechea E, Palomera L, de Arriba F, Esseltine DL, Cakana A, Pei L, van de Velde H, Miguel JS (2016) Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA\/GEM05 trials. Ann Hematol 95:2033\u20132041","journal-title":"Ann Hematol"},{"key":"1602_CR18","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","volume":"101","author":"N Mitsiades","year":"2003","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377\u20132380","journal-title":"Blood"},{"key":"1602_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ebiom.2015.05.016","volume":"2","author":"DS Pitcher","year":"2015","unstructured":"Pitcher DS, de Mattos-Shipley K, Tzortzis K, Auner HW, Karadimitris A, Kleijnen MF (2015) Bortezomib amplifies effect on intracellular proteasomes by changing proteasome structure. EBioMedicine 2:642\u2013648","journal-title":"EBioMedicine"},{"key":"1602_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ebiom.2015.07.009","volume":"2","author":"J Roelofs","year":"2015","unstructured":"Roelofs J (2015) Proteasome inhibition by bortezomib: a left hook and a right punch. EBioMedicine 2:619\u2013620","journal-title":"EBioMedicine"},{"key":"1602_CR21","doi-asserted-by":"publisher","first-page":"e56132","DOI":"10.1371\/journal.pone.0056132","volume":"8","author":"TB Shabaneh","year":"2013","unstructured":"Shabaneh TB, Downey SL, Goddard AL, Screen M, Lucas MM, Eastman A, Kisselev AF (2013) Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS One 8:e56132","journal-title":"PLoS One"},{"key":"1602_CR22","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IGH, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol 30:2946\u20132955","journal-title":"J Clin Oncol"},{"key":"1602_CR23","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","volume":"31","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Goldschmidt H, Rosinol L, Blad\u00e9 J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P (2013) Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31:3279\u20133287","journal-title":"J Clin Oncol"},{"key":"1602_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000205884","volume":"78","author":"L Sviland","year":"1987","unstructured":"Sviland L, Leggat H, Harris AL, Bird G, Proctor SJ (1987) Short course intermediate dose intravenous melphalan therapy in myeloma--relation to early emergence of drug resistance (phase II study). Acta Haematol 78:233\u2013238","journal-title":"Acta Haematol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-018-01602-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-018-01602-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-018-01602-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T19:18:32Z","timestamp":1576351112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-018-01602-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,15]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1602"],"URL":"https:\/\/doi.org\/10.1007\/s00210-018-01602-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"type":"print","value":"0028-1298"},{"type":"electronic","value":"1432-1912"}],"subject":[],"published":{"date-parts":[[2018,12,15]]},"assertion":[{"value":"8 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}